Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANJINTI vs SYLVANT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.
Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.
Adjuvant treatment of HER2-overexpressing breast cancer,Metastatic HER2-positive breast cancer (first-line in combination with chemotherapy),Neoadjuvant treatment of locally advanced or early stage HER2-positive breast cancer
Treatment of multicentric Castleman disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,Off-label: Treatment of cytokine release syndrome, Castleman disease in HIV-positive or HHV-8-positive patients, and other IL-6-driven conditions.
4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.
11 mg/kg intravenously every 3 weeks, administered over 1 hour.
Terminal elimination half-life: 28–38 days (mean ~32 days). Consistent with Ig G1 monoclonal antibody clearance; supports every-3-week dosing for sustained exposure
Terminal half-life ~21 days (range 14–28 days) at steady state; supports every-3-week dosing.
Pertuzumab and trastuzumab are monoclonal antibodies degraded via catabolic pathways similar to endogenous Ig G, primarily through reticuloendothelial system; not metabolized by CYP450 enzymes. Hyaluronidase is degraded by hyaluronidases in tissues.
Siltuximab is a monoclonal antibody; its metabolism is not typical. It is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. No specific metabolic enzymes are involved.
Primarily hepatic metabolism; renal elimination of intact drug is minimal (<1%). Biliary/fecal excretion accounts for the majority of elimination (>90%)
Renal (minimal as intact Ig G), primarily catabolized to amino acids; no significant biliary/fecal elimination.
Non-specific binding to plasma proteins is negligible; >99% of trastuzumab circulates unbound (free). No significant binding to albumin or alpha-1-acid glycoprotein
No specific protein binding; Ig G4 monoclonal antibody does not bind significantly to plasma proteins.
Mean Vd: 2.9–4.5 L/kg (approximately 200–300 L for a 70 kg patient), indicating distribution into tissues including lymph and interstitial space
Vd ~6.0 L (0.08 L/kg for 70 kg adult); primarily confined to vascular space and interstitial fluid.
Not applicable for oral administration; only IV administration is approved. Bioavailability by IV route is 100%
IV administration: 100% bioavailable; no other routes approved.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment recommended for Child-Pugh A or B. Safety and efficacy not established in Child-Pugh C; use only if benefit outweighs risk.
No formal studies in hepatic impairment. Use with caution in patients with moderate to severe impairment (Child-Pugh B or C).
Weight-based dosing: Same as adult schedule (mg/kg). Safety and efficacy established for children ≥2 years with HER2-overexpressing tumors; dosing based on body weight. Maximum area under the curve similar to adults.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment. Increased incidence of cardiac dysfunction in elderly; monitor left ventricular ejection fraction (LVEF) frequently. Dose modifications for toxicity same as adults.
No specific dose adjustment recommended; select dose with caution due to higher frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.
WARNING: CARDIOTOXICITY. KANJINTI can cause subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF. Evaluate cardiac function before and during treatment. Discontinue for clinically significant decline.
None.
Cardiotoxicity (LVEF decline, heart failure),Infusion-related reactions (including anaphylaxis),Pulmonary toxicity (interstitial lung disease, pneumonitis),Embryo-fetal toxicity (oligohydramnios, fetal renal impairment),Exacerbation of chemotherapy-induced neutropenia
Risk of serious infections: Evaluate for active infections prior to initiating therapy; monitor for infections during treatment.,Hypersensitivity reactions: Infusion-related reactions may occur; premedicate and monitor during infusion.,Hematologic effects: Neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts.,Hepatotoxicity: Elevations of liver enzymes have been reported; monitor liver function.,Immunogenicity: Anti-drug antibodies may develop and affect efficacy or safety.,Vaccinations: Live vaccines should not be administered during treatment.
Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any component of KANJINTI
Known severe hypersensitivity to siltuximab or any of its excipients.,Active severe infections until infection is controlled.
No known food interactions. Avoid grapefruit juice unless directed by healthcare provider.
No clinically significant food interactions have been reported. Take with or without food as tolerated.
KANJINTI (trastuzumab) is an Ig G1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when administered during the second and third trimesters. Exposure during organogenesis (first trimester) may also carry risks, but data are limited. Use is contraindicated in pregnancy.
SYLVANT (siltuximab) is a monoclonal antibody (Ig G1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Animal studies have shown no evidence of teratogenicity in cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, there are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (IL-6 inhibition), there is a potential risk of fetal harm due to interference with normal immune development and hematopoiesis. Therefore, SYLVANT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Trastuzumab is excreted in human milk at low levels. The milk-to-plasma ratio is unknown. Due to the potential for adverse effects in the breastfeeding infant, advise women to discontinue breastfeeding during treatment and for 7 months after the last dose.
It is not known whether siltuximab is excreted in human milk. However, maternal Ig G is known to be present in breast milk, and monoclonal antibodies can be excreted in low amounts. The M/P ratio is not available. The effects on the breastfed infant and on milk production are unknown. Because of the potential for adverse reactions in nursing infants from siltuximab, breastfeeding should be discontinued during treatment and for at least 90 days after the last dose.
No specific dose adjustment is recommended in pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (increased plasma volume, altered renal clearance) may affect trastuzumab exposure, but no dose adjustment guidelines exist. Therapy should be discontinued if pregnancy occurs.
No specific dose adjustments are recommended for SYLVANT during pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may occur, but no data are available to guide adjustments. The drug should be used with caution, and the dose should be guided by clinical response and tolerability.
KANJINTI (trastuzumab-anns) is a biosimilar to trastuzumab. Administer as IV infusion; observe for infusion reactions. Do not mix with dextrose solutions. Confirm HER2 overexpression before use (IHC 3+ or FISH+). Monitor left ventricular ejection fraction (LVEF) at baseline and every 3 months. Contraindicated in patients with LVEF <50% or significant decline. Cardiotoxicity risk increases with anthracycline pre-treatment. Use with caution in pregnant women; may cause fetal harm.
SYLVANT (siltuximab) is an IL-6 antagonist indicated for idiopathic multicentric Castleman disease (MCD). Monitor for infections due to immunosuppression; do not administer live vaccines. Infusion reactions possible; premedicate with antihistamines/acetaminophen if needed. Assess baseline hepatic function, as transaminase elevations may occur. Discontinue if severe infusion reaction or anaphylaxis.
Take only under prescription from a doctor.,Report any chest pain, shortness of breath, or swelling of ankles immediately.,Avoid pregnancy while on treatment; use effective contraception during and for 7 months after last dose.,Do not breastfeed during treatment and for 7 months after last dose.,Regular heart function tests (echocardiogram or MUGA) will be performed.,You may experience flu-like symptoms (fever, chills) after infusion; these are usually manageable.
Report signs of infection (fever, chills, sore throat) immediately.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for 3 months after.,Notify your doctor if you experience symptoms of infusion reaction (headache, nausea, dizziness, rash).,Regular blood tests will be required to monitor liver function and blood counts.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANJINTI vs SYLVANT, answered by our medical review team.
KANJINTI is a Monoclonal Antibody Antineoplastic that works by KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.. SYLVANT is a Monoclonal Antibody Antineoplastic that works by Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANJINTI and SYLVANT depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANJINTI is: 4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.. The standard adult dose of SYLVANT is: 11 mg/kg intravenously every 3 weeks, administered over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KANJINTI and SYLVANT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KANJINTI is classified as Category C. KANJINTI (trastuzumab) is an IgG1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when ad. SYLVANT is classified as Category C. SYLVANT (siltuximab) is a monoclonal antibody (IgG1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Anim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.